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 30 
Summary 31 
Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced 32 
mobility, skeletal complications and treatment-related events reduce quality of life. 33 
Numerous randomised controlled trials have evaluated pharmacological interventions to 34 
treat bone metastases. The primary outcomes used have evolved over the past 25 years; 35 
from improvement in pain to time-to-first skeletal related event (SRE). An SRE consists of 36 
pathological fracture, spinal cord compression or need for radiotherapy or surgery to the 37 
bone. Currently used outcomes can detect small differences between interventions. 38 
However there are several limitations to SRE-related outcomes. In this article we illustrate 39 
the evolution of outcomes used in RCTs, critically appraising current outcomes used and 40 
proposing that more patient-centred outcomes are needed.  41 
 42 
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Introduction  54 
Bone is a common location for metastatic spread of cancer. Approximately 5% of women 55 
with breast cancer will develop bone metastases within five years of diagnosis (1). In lung 56 
cancer, it is estimated that 36% of patients have bone involvement at death (2). Bone 57 
metastases are considerably more common in prostate cancer. Bubendorf and colleagues 58 
(3), performed autopsies on over 1,500 men with prostate cancer and found that 90% had 59 
evidence of bone involvement. Any cancer has the potential to metastasise to bone, but the 60 
commonest causes of bone metastases are cancers of the breast, prostate, lung, bladder, 61 
thyroid and kidney.  62 
Bone metastases are associated with reduced survival, increased complications and 63 
decreased quality of life (4,5). The clinical sequelae of bone metastases vary considerably. 64 
Pharmacological interventions are available to improve symptoms and reduce the risk of 65 
complications. Recent trials have used a composite outcome, known as skeletal related 66 
events (SRE) (6-11), which consists of pathological fracture, spinal cord compression, or 67 
need for radiation or surgery to the bone.  68 
The outcomes chosen by trialists have wide ranging consequences; policy makers use this 69 
information to assist decision-making, future trial outcomes are designed in the context of 70 
previous research and the focus of treatment for clinicians and patients can be affected. In 71 
pharmacological trials of bone metastases, the SRE composite outcome has evolved over 72 
the past 25 years. In this article, we describe and explain the trend in outcomes used in 73 
pharmacological trials for bone metastases, critically appraising the current SRE outcome 74 
and propose that a more patient-centred outcome should be adopted.  75 
 76 
Overview of pathophysiology 77 
Metastatic disease within bone causes structural weakness by dysregulation of osteoblasts 78 
and osteoclasts. Pathophysiology of bone metastases has been illustrated by the “seed and 79 
soil” hypothesis (12). Bone marrow is an ideal “soil” because of the presence of an excellent 80 
reserve of micronutrients and growth factors. A good blood supply allows easy 81 
transportation of the “seed” (tumour cells).  82 
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Tumour cells interfere with the balance of osteoblasts and osteoclasts. Osteoblasts are 83 
responsible for bone formation, whereas osteoclasts resorb bone. Their synergistic action 84 
results in a constant turnover of bone and is dependent on a complex cascade of growth 85 
factors, cytokines, receptors and intracellular signals. There are a number of important 86 
mediators of bone resorption including dickkopf homolog 1 (Dkk1), stromal derived factor-1 87 
alpha (SDF-1a), transforming growth factor beta (TGF-β), macrophage inflammatory protein-88 
1a (MIP-1α), c-MET, SRC kinase and proteases including cathepsins and matrix 89 
metalloproteases.  One such mediator is receptor activator of nuclear factor-ĸB ligand 90 
(RANKL), which induces osteoclast activity (and subsequent bone resorption) and is the 91 
target of the drug denosumab. 92 
Pharmacological therapies may be more effective in a certain type of bone metastases . For 93 
example, zoledronic acid has been shown to be more effective than pamidronate in lytic 94 
bone metastases in breast cancer (13). The nature of bone metastases depends on the 95 
extent to which osteoclasts or osteoblasts are activated. An over-activity of osteoclasts 96 
results in mainly lytic (osteolytic) lesions, whereas over-activity of osteoblasts results in 97 
sclerotic (ostesclerotic or osteoblastic) lesions. Both sclerotic and lytic lesions cause 98 
disruption of the normal bone architecture resulting in structural weakness. Based on 99 
radiological appearance bone metastases can be categorised as sclerotic, lytic or mixed. 100 
Generally speaking, prostate cancer results in mainly sclerotic lesions and breast cancer lytic 101 
lesions (14). However, bone metastases should be considered in the context of a spectrum 102 
of lesions from lytic to sclerotic, with no lesion being purely lytic or sclerotic.  103 
 104 
Spectrum of clinical sequelae associated with bone metastases 105 
An understanding of the spectrum of the clinical sequelae associated with bone metastases 106 
is crucial when considering trial outcomes. The clinical sequelae associated with bone 107 
metastases are three-fold; 1) reduced survival, 2) increased risk of complications and 3) 108 
decreased quality of life. The sequelae are different for each patient, depending on location, 109 
type and number of bone metastases. 110 
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The main complications related to bone metastases are pathological fracture, 111 
hypercalcaemia, spinal cord compression and treatment-related events. Pathological 112 
fractures are caused by increased bone fragility due to sclerotic or lytic lesions. Fractures of 113 
the long bones or axial skeleton are commonest. Pathological fractures can range from 114 
asymptomatic fractures incidentally identified on radiological investigation, to disabling long 115 
bone fractures causing immobility.  116 
Spinal cord compression (SCC) is the most serious complication. It can be caused by an 117 
impinging fracture or direct tumour growth. Paraplegia can ensue if SCC is not diagnosed at 118 
a sufficiently early stage or if the compression is not amenable to treatment. As with 119 
pathological fracture, there is a breadth of possible clinical outcomes, from mild sensory loss 120 
to complete paraplegia. Hypercalcaemia is caused by release of calcium from bone 121 
metastases and dysregulation of normal calcium homoeostasis. 122 
There is a clear association between reduced survival and bone metastases. In prostate 123 
cancer, five year survival drops from 56% to 3% with the presence of bone metastases (4). 124 
Breast cancer with associated bone metastases is associated with a five year survival of 20% 125 
(5). However reduced survival with bone metastases mainly reflects disease progression, 126 
rather than mortality directly caused by bone metastases. For example, in breast cancer 127 
median survival is estimated to be 2.1 years for patients with bone metastases only, 128 
compared with 1.6 years for patients with bone and visceral metastases (15). Bone 129 
metastases can cause mortality by complications, such as hypercalcaemia, spinal cord 130 
compression or pathological fractures. Saad and colleagues (16) found that pathological 131 
fractures were associated with reduced survival, an association which has been supported 132 
by other studies (4,5). Whether or not the reduced survival is caused by a pathological 133 
fracture or a confounder, such as disease progression, is not clear.   134 
Quality of life is decreased by a convergence of increased pain, reduced mobility and 135 
incidence of complications. Pain associated with bone metastases is often severe and can be 136 
difficult to control with analgesia. Mobility is reduced by asthenia, bone pain, pathological 137 
fractures, nerve root compression or spinal cord compression. Subsequently quality of life 138 
decrement can vary dramatically between patients. 139 
 140 
6 
 
Current treatment options 141 
Current treatment for bone metastases includes supportive care with or without bone 142 
targeting drugs as well as treatment of the underlying systemic malignancy. Supportive care 143 
consists of therapies tailored to each individual patient, eg, analgesics, radiotherapy or 144 
surgery to bone to treat or prevent fractures. There are currently two main classes of bone 145 
metabolism targeted drugs used in the treatment of malignant bone disease; 146 
bisphosphonates and a RANKL-targeted antibody, denosumab.  147 
Bisphosphonates inhibit osteoclasts, reducing bone resorption. There are currently four 148 
bisphosphonates licensed for treatment of bone metastases – zoledronic acid (all advanced 149 
malignancies), disodium pamidronate (breast cancer or multiple myeloma), ibandronic acid 150 
(breast cancer only) and sodium clodronate (breast cancer or multiple myeloma). Current 151 
National Institute for Health and Clinical Excellence (NICE) guidelines recommend that all 152 
patients with symptomatic bone metastases secondary to breast or castration resistant 153 
prostate cancer for whom conventional treatments have failed should be considered for 154 
treatment with bisphosphonates (Clinical Guideline 81 (101) and Clinical Guideline 58 (102)). 155 
Published guidelines by the American Society of Clinical Oncology recommend the use of 156 
bisphosphonate for all patients with bone metastases secondary to breast cancer (17). 157 
Denosumab is a fully human monoclonal antibody that inhibits RANKL. It has been evaluated 158 
through three pivotal trials (9-11) and recently licensed by the European Medicines Agency 159 
for the prevention of skeletal related events in bone metastases from solid tumours (103). 160 
Denosumab has also been studied for the prevention of bone metastases (Smith 11). 161 
New pharmacological interventions, such as SRC kinase inhibitors (18) and c-MET inhibitors 162 
(19), have been tested in early phase clinical studies and will soon be evaluated in phase 3 163 
trials.  164 
 165 
What outcomes have been used and are currently used? 166 
Assessment of pharmacological interventions is challenging because of the spectrum of 167 
clinical sequelae from bone metastases. A number of different outcome measures have 168 
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been used in clinical trials over the past 25 years (20-51). Table 1 shows the evolution and 169 
trend of primary and secondary outcomes. 170 
Very early trials (20, 22, 23) only included patients with bone pain at baseline and 171 
subsequently assessed improvement of pain. The majority of these trials were performed in 172 
prostate cancer, where metastatic bone pain can often be severe despite strong analgesics. 173 
In the 1990s, some trials started using skeletal events, such as pathological fracture or need 174 
for radiotherapy as primary outcomes (25, 35), but not as the SRE composite outcome. 175 
Quality of life measures and biochemical markers were also increasingly used during this 176 
period. 177 
In 2000 Lipton and colleagues (36), reported the results of two randomised controlled trials 178 
(52, 53). The primary outcome in these trials was skeletal morbidity rate (SMR), defined as 179 
“the ratio of the number of skeletal complications experienced by a patient divided by the 180 
time on the trial for that patient (expressed as the number of events/year)”. Skeletal 181 
complications were a composite endpoint and included pathological fracture, need for 182 
radiotherapy or surgery, spinal cord compression or hypercalcaemia.  These skeletal 183 
complications would soon become known under the term skeletal-related events (SREs).  184 
Within the composite endpoint of SREs, some trials would include hypercalcaemia and/or 185 
change in anti-neoplastic medication.  In recent trials, patients are screened radiologically 186 
for SREs on a regular basis, with both new asymptomatic and symptomatic fractures being 187 
included (9-11). Including asymptomatic events may overestimate treatment effects. 188 
However, some may argue that including asymptomatic fracture is appropriate, since it is 189 
likely that these fractures will become symptomatic. The relationship between such ‘events’ 190 
and actual morbidity remains far from clear. 191 
 192 
Some authors argued that the proportion of patients requiring radiotherapy is the most 193 
appropriate outcome, since radiotherapy is the commonest SRE and repeated need for 194 
treatment would reduce quality of life (compared with pathological fractures which may be 195 
asymptomatic and not impact quality of life) (37). On the other hand, radiotherapy is 196 
accessible to most patients and can be highly effective in controlling bone pain with minimal 197 
toxicity, thus minimising the actual impact of the ‘event’ on quality of life. 198 
 199 
8 
 
Two trials evaluating ibandronic acid used an evolution of SMR, the skeletal morbidity 200 
period rate (SMPR) (42,43).  The SMPR was introduced to overcome criticisms that SREs are 201 
often related to previous SREs. For example, a patient who suffers a pathological fracture 202 
may subsequently have surgery. This would be classified as two SREs.  SMPR defines a 203 
period as 12 weeks. The trial lasted for 96 weeks, therefore patients who completed the 204 
trial would undergo eight 12-week periods. For each patient, the number of periods with a 205 
new SRE was calculated and divided by the total number of 12-week periods on study.  206 
However this does not allow for difference in time on-study. For example, a patient who 207 
leaves the trial after 12 week without an SRE is given the same score as a patient who 208 
finished the trial after 96 weeks without an SRE. To overcome this, authors used a ‘revised 209 
rate ratio’ using the calculation: 210 
 211 
𝑆𝑀𝑃𝑅 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑟𝑖𝑜𝑑𝑠 𝑤𝑖𝑡ℎ 𝑎 𝑛𝑒𝑤 𝑆𝑅𝐸 + 1
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 12 𝑤𝑒𝑒𝑘 𝑝𝑒𝑟𝑖𝑜𝑑𝑠 𝑜𝑛 𝑠𝑡𝑢𝑑𝑦 + 0.5  
 212 
Therefore, the more 12 week periods a patient accumulates without an SRE the lower the 213 
SMPR will be. The aim is to prevent overestimation of the treatment effect. However the 214 
SMPR could have the opposite effect and underestimate effectiveness, if several 215 
independent SREs occurred within one period. 216 
 217 
Three pivotal trials evaluating zoledronic acid, compared with pamidronate or placebo, 218 
addressed the criticism of dependent SREs by introducing a 21 day window (6-8); after a SRE 219 
occurs, no further SREs are counted for 21 days.   220 
 221 
The primary outcome in the zoledronic acid trials (6-8) was the proportion of patients with 222 
at least one on-study SRE (including a 21 day window), but the trials also introduced two 223 
more outcomes; time-to-first SRE and time-to-first and subsequent SRE. These outcomes 224 
identify differences in delay of events (first and subsequent), even if the total number of 225 
events in each group are equal.  226 
 227 
Time-to-first and subsequent SRE uses multiple event analysis (MEA). This method, first 228 
described by Andersen and Gill (54), includes a measure of both time and number of events. 229 
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It has been criticised because it does not differentiate between participants who have died 230 
and those who have left the trial (55). Other methods which incorporate mortality have 231 
been proposed (56, 57), but the Andersen-Gill method remains the most widely used. 232 
 233 
The most recent trials, comparing denosumab with zoledronic acid, have used time-to-first 234 
SRE as the primary endpoint (9-11). Time-to-first and subsequent SRE is included as a 235 
secondary outcome. 236 
 237 
 238 
 Expert Commentary 239 
 240 
What are the important outcomes for patients with bone metastases? 241 
Trials should primarily assess the outcomes that are most important to patients and 242 
subsequently outcomes most important to the health and social services. Patients should be 243 
able to understand the outcome and evaluate the potential benefits that treatment may 244 
bring to them. 245 
There are four main outcomes that are important to patients with bone metastases; 1) 246 
overall survival 2) quality of life 3) serious complications (such as spinal cord compression or 247 
long bone pathological fracture) and 4) treatment administration and adverse events. 248 
Quality of life measures encompass a number of different events and symptoms, such as 249 
pain and reduced mobility.  250 
Since health and social care is delivered in an environment of limited resources with 251 
opportunity costs, relevant outcomes relate to resource use, such as management of 252 
disease progression and complications, administration of treatments and provision of care.  253 
 254 
What are the strengths and limitations of the current outcomes? 255 
 256 
SRE composite outcome 257 
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The composite SRE outcome allows for increased power and efficiency. To detect clinically 258 
meaningful differences in each event (such as spinal cord compression), large study 259 
numbers would be needed. Furthermore, it could be argued that one composite outcome is 260 
easier for clinicians, patients and researchers, opposed to several individual outcomes.  261 
However there are significant limitations of the SRE composite outcome. The SRE composite 262 
outcome includes a wide spectrum of outcomes and is therefore of little use to patients. An 263 
asymptomatic fracture and spinal cord compression leading to paraplegia are given equal 264 
weight. For example, in the study performed by Saad and colleagues (6), zoledronic acid 265 
reduced the absolute risk of experiencing an on-study SRE by 11% (95% CI 1.8% to 20.3%) 266 
compared to placebo. The obvious question from a patient’s perspective is, do I have an 267 
11% risk reduction of an asymptomatic event (asymptomatic fractures and change in anti-268 
neoplastic medications were included) or a serious complication (spinal cord compression)? 269 
The answer is the patient has an 11% absolute risk reduction of experiencing any SREs, but a  270 
9% (95%CI 1.8% to 16.3%) absolute risk reduction of experiencing a pathological fracture 271 
and 2.5% (95%CI -1.8 to 6.9) absolute risk reduction in spinal cord compression. In fact, 272 
when the SRE outcomes are divided in this study, only pathological fractures show a 273 
significant difference.  The trial included approximately 205 patients in each arm and would 274 
require substantially more to be sufficiently powered to detect differences in individual 275 
SREs.  276 
The SRE outcome is further complicated by including both treatments (need for surgery or 277 
radiotherapy) and complications (pathological fracture and spinal cord compression).  278 
Moreover the SRE outcome does not directly measure bone pain or mobility. Although need 279 
for radiotherapy is an indirect measure of bone pain, it would not be considered specific. 280 
Some patients may have generalised widespread pain that is not suitable for radiotherapy.  281 
The SRE composite outcome can be subject to over-estimation. Frequent radiological 282 
screening of patients for SREs will identify more pathological fractures earlier. A study by 283 
Trinkaus and colleagues (58) compared the SRE frequency in patients treated with 284 
intravenous bisphosphonates in a “real life” setting, with the trial setting. The authors found 285 
a considerably lower incidence of SREs in the “real life” setting. 286 
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 287 
SRE incidence versus time to event analysis 288 
The trial analysis methodology has evolved over the past 25 years to detect smaller 289 
differences. Time to first and time to first-and-subsequent analyses will detect very small 290 
differences between treatments. The need to detect small differences may be warranted, as 291 
new interventions are compared with active comparators. Statistically significant differences 292 
may be demonstrated, but it is important to ensure that these are clinically meaningful. 293 
Time to event analyses and multiple event analyses reflect a delay, not prevention, of 294 
complications. Time-to-first SRE is a relatively simple measure. However multiple event 295 
analysis adds an additional layer of complexity that may prove difficult for patients and their 296 
physicians to understand. In addition, multiple event analyses are more likely to show small 297 
differences between treatments that may not be clinically meaningful. 298 
 299 
Five year view 300 
What would be the ideal outcome? 301 
The key question is, does a reduction in risk of SREs (measure with SRE incidence or time to 302 
event analysis) directly correlate with a reduction in decreased quality of life? If SRE events 303 
do not correlate with quality of life the validity of the SRE outcome is questionable. A 304 
disease specific quality of life measure should be sensitive to changes in bone pain, 305 
complications, mobility and treatment toxicity. Unfortunately detailed quality of life and 306 
pain outcomes have not been published to allow this sort of analysis. Some pain and quality 307 
of life outcomes have been published in abstract form (59-65), but generally continuous 308 
outcomes have been converted into categorical data and only selective subgroups reported.  309 
The outcomes chosen by trialists are of paramount importance to patients, clinicians, 310 
researchers and the clinical pharmacology community. Outcomes affect the interpretation 311 
of effectiveness of the interventions, design of future trials, licensing indications and 312 
possibly the attention of clinicians. Table 1 illustrates how outcomes chosen by trialists 313 
affect future trials. The term SRE has appeared in licensing indications. The European 314 
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Medicines Agency has licensed denosumab for the “prevention of skeletal related events in 315 
bone metastases from solid tumours” (103).  The primary goal of clinicians and the 316 
pharmacology community should be to improve the quantity and quality of life for patients 317 
with bone metastases. Trials that focus on preventing SREs may divert the attention of 318 
clinicians from this goal.  319 
 320 
An analysis correlating SRE outcome and quality of life or pain scores is needed. Both 321 
generic (e.g. EQ5D) and disease specific (e.g. FACT) quality of life measures should be used. 322 
However this will only be possible if detailed quality of life data are published. Alternatively 323 
a mixed-method study measuring qualitative data alongside a RCT could be designed to 324 
evaluate the impact of individual SREs on patients.  325 
We propose that trialists move more towards patient-relevant outcomes. Primary outcomes 326 
should include patient-centred outcomes such as direct measures of pain and mobility. A 327 
robust composite endpoint which accurately reflects the benefits of a new treatment is 328 
unlikely to be found. Disease specific quality of life measures may be the closest trialists will 329 
get to a composite endpoint that encapsulates all benefits. Alternatively several individual 330 
outcomes could be reported, such as pain scores, mobility indices, incidence of 331 
fractures/spinal cord compression/hypercalcaemia, but this is unlikely to be acceptable for 332 
the purposes of drug registration. In the meantime we recommend that the SRE outcome 333 
should be reported alongside quality of life scores and be interpreted with caution.   334 
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Key issues 335 
• Bone metastases are associated with a spectrum of clinical sequelae 336 
• Numerous randomised controlled trials have evaluated pharmacological 337 
interventions 338 
• Early trials measured improvement of bone pain, most recent trials assess time-to-339 
first skeletal-related event (SRE) 340 
• The composite SRE endpoint consists of pathological fracture, spinal cord 341 
compression or need for radiotherapy or surgery to bone, with each component 342 
given equal weight 343 
• The SRE endpoint is of little use to patients since it encompasses a wide spectrum of 344 
clinical events 345 
• It is unclear if improvement in SRE outcomes directly correlate with improvements in 346 
quality of life 347 
• An endpoint that reflects the most important outcomes to patients is needed 348 
• It is unlikely that a robust composite outcome will be found 349 
• Disease specific quality of life measures may be the closest trialists get to an 350 
outcome that encompasses as many treatment benefits as possible. 351 
 352 
 353 
 354   355 
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Table 1: Primary and secondary outcomes  
First author and 
year 
Primary  
tumour 
Intervention Comparison Primary outcome Secondary outcomes 
Buchali 1988 
(20) 
Prostate Strontium (iv) Placebo Improvement in bone pain (subjective reporting) Overall survival Effects on blood cell count 
Elomaa 1988 
(21) 
Breast Clodronate (oral) Placebo Biochemical markers Survival 
Adami 1989 
(22) 
Prostate Clodronate (iv+im+oral) Placebo Improvement in bone pain (analgesic use and VAS) Haematological toxicity 
Smith 1989 (23) Prostate Etidronate (iv+oral) Placebo Improvement in bone pain (analgesic use and VAS)  
Elomaa 1992 
(24) 
Prostate Clodronate (iv) Placebo Improvement in bone pain (subjective and analgesic use) Survival Serum calcium 
Paterson 1993 
(25) 
Breast Clodronate (oral) Placebo Incidence of HCM, fracture and need for radiotherapy Cumulative skeletal morbidity Survival Bone pain 
Kylmala 1993 
(26) 
Prostate Clodronate (iv) Open Improvement in bone pain (subjective and analgesic use) Bone markers Radiological appearance Biochemical markers Survival 
Porter 1993 
(27) 
Prostate Strontium (iv) Placebo Delay and improvement of pain (scores and analgesic use) Survival Need for radiotherapy Quality of life Biochemical markers 
Quilty 1994 
(28) 
Prostate Strontium (iv) Radiotherapy Improvement in bone pain (subjective and analgesic use) Performance status Survival 
Robertson 1995 
(29) 
OST Clodronate (oral) Placebo Improvement in bone pain (analgesic use and VAS) Survival 
O’Rouke 1995 
(30) 
OST Clodronate (oral) Placebo Biochemical markers Improvement in bone pain 
Kylmala 1997 
(31) 
Prostate Clodronate (iv+oral) Placebo Improvement in bone pain (WHO classification) Performance status Biochemical markers Radiological progression 
Strang 1997 
(32) 
Prostate Clodronate (iv) Placebo Improvement in bone pain (analgesic use and VAS)  
Piga 1998 (33) OST Clodronate (oral) Placebo Performance status Improvement in bone pain (analgesic use and VAS) 
Arican 1999 
(34) 
Prostate Clodronate (oral) Placebo Improvement in bone pain (analgesic use and VAS) Performance status Bone markers 
Kristensen 
1999 (35) 
Breast Clodronate (oral) Open Incidence of HCM, fracture or need for radiotherapy Bone markers Pain 
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Quality of life (HADs and EORTC-QLQ) 
Lipton 2000 
(36) 
Breast Pamidronate (iv) Placebo SMR* Incidence of SRE* Pain  Quality of life (Spitzer index) Performance status Bone markers   
Berenson 2001 
(37) 
OST Zoledronic acid Pamidronate (iv) Proportion of patients requiring radiotherapy Incidence of SREs* Bone mineral density Performance status Bone pain 
Jagdev 2001 
(38) 
OST Clodronate (oral) Pamidronate (iv) Improvement in pain (subjective response) Biochemical markers 
Saad 2002 (6) Prostate Zoledronic acid Placebo Proportion of patients with ≥1 SRE† Time to first SRE† SMR† Time to disease progression Bone markers Quality of life 
Small 2003 (39) Prostate Pamidronate (iv) Placebo Improvement in bone pain (analgesic use and BPI) Proportion with SRE* SMR Mobility (walking speed) Tumour markers 
Ernst 2003 (40) Prostate Clodronate (iv) Placebo Improvement in bone pain (palliative response criteria (moore 94 JCO) Quality of life Symptomatic progression PSA response Incidence of HCM, radiotherapy and pathological fractures 
Dearnaley 2003 
(41) 
Prostate Clodronate (oral) Placebo Symptomatic bone progression free survival Survival  Biochemical markers Bone pain 
Body 2003 (42) Breast Ibandronate (iv) Placebo SMPR** Bone pain Performance status Survival Bone markers 
Rosen 2003a 
(7) 
Breast Zoledronic acid Pamidronate (iv) Proportion of patients with ≥1 SRE Time to first SRE Time to each SRE SMR MEA Survival Performance status 
Rosen 2003b OST Zoledronic acid Placebo Proportion of patients with ≥1 SRE Time to first SRE 
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(8) SMR MEA Time to bone progression Survival Bone markers Bone pain 
Body 2004 (43) Breast Ibandronate (oral) Placebo Skeletal morbidity period rate** Bone pain Quality of life (EORTC-QLQ) 
Kohno 2005 
(44) 
Breast Zoledronic acid Placebo Ratio of SRE rate Proportion of patients with ≥1 SRE* Time to first SRE* Multiple event analysis* Bone pain (BPI) 
Nilsson 2005 
(45) 
Prostate Strontium (iv) FEM Improvement in bone pain (analgesic use and VAS) Performance status 
Brown 2007 
(46) 
OST Clodronate (oral) Placebo Bone markers Bone pain (VAS) 
Heras 2007 (47) Colorectal Ibandronate (iv) Placebo Proportion of patients with ≥1 SRE† Time to first SRE† SMR† Time to progression of bone lesions Bone markers 
Mystakidou 
2008 (48) 
OST Ibandronate (oral) Ibandronate (iv) Clinical response based on radiographic appearance of lesions Bone pain (BPI) Quality of life (FACT-G) 
Heras 2009 (49) Breast Ibandronate (iv) Placebo Proportion of patients with ≥1 SRE† Time to first SRE† MEA† 
Zaghloul 2010 
(50) 
OST Zoledronic acid Placebo Proportion of patients with ≥1 SRE* Time to first SRE* Pain score Overall survival 
Zhao 2011 (51) OST Zoledronic acid Open Bone markers Survival Incidence of SREs* 
Stopeck 2010 
(10) 
Breast Denosumab Zoledronic acid Time to first SRE (non-inferiority) Time to first SRE (superiority) MEA Overall survival Bone markers Fizazi 2011 (11) Prostate Denosumab Zoledronic acid Henry 2011 (9) OST Denosumab  Zoledronic acid  
OST = other solid tumours, iv = intravenous, im = intra-muscular, FEM = 5-FU, epirubicin and mitomycin, VAS = visual analogue scale, EPRTC-QLQ = European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire, SRE = skeletal related event, MEA = multiple event analysis, BPI = brief pain inventory, VAS – visual 
analogue scale, SMR = skeletal morbidity rate   
* includes hypercalcaemia ** revised event ratio method, † = includes change in anti-neoplastic therapy,  
 
